-

03:59:17 PM

VERV Stock News

VERV - Verve Therapeutics Inc

09/22/22 6:30 AM

Nasdaq : VERV

conferences

Verve Therapeutics to Participate in Upcoming Investor Conferences

Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that management will participate in the following upcoming

RHEA-AI

neutral

09/21/22 6:30 AM

Nasdaq : VERV

clinical trial

Verve Therapeutics Announces Clearance of Clinical Trial Authorisation Application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia

Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the clearance of its Clinical Trial Authorisation (CTA)

RHEA-AI

neutral

08/22/22 6:30 AM

Nasdaq : VERV

clinical trial

Verve Therapeutics Highlights Preclinical Data Supporting Nomination of VERVE-201 ANGPTL3 Product Candidate at the European Society of Cardiology 2022 Congress

Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced new preclinical data supporting the nomination of the

RHEA-AI

positive

08/09/22 6:30 AM

Nasdaq : VERV

earnings

Verve Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results

Over $300 Million in Capital Added to Balance Sheet, Supporting an Operating Runway into Second Half of 2025 Patient Dosing Underway with Lead Candidate, VERVE-101, for Treatment of Heterozygous Familial Hypercholesterolemia; Regulatory Clearances in the United Kingdom and United States Anticipated

RHEA-AI

positive

07/25/22 4:01 PM

Nasdaq : VERV

offering

Verve Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Verve Therapeutics, Inc. (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the closing of its previously announced upsized

RHEA-AI

neutral

07/21/22 6:30 AM

Nasdaq : VERV

offering

Verve Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

Verve Therapeutics, Inc. (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pricing of its upsized underwritten public offering

RHEA-AI

neutral

07/20/22 4:02 PM

Nasdaq : VERV

offering

Verve Therapeutics Announces Proposed Public Offering of Common Stock

Verve Therapeutics, Inc. (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that it has commenced an underwritten public offering of

RHEA-AI

neutral

07/20/22 4:01 PM

Nasdaq : VERV

Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Verve Therapeutics, Inc. (Nasdaq: VERV) today

RHEA-AI

positive

07/12/22 6:30 AM

Nasdaq : VERV

Verve Therapeutics Doses First Human with an Investigational In Vivo Base Editing Medicine, VERVE-101, as a Potential Treatment for Heterozygous Familial Hypercholesterolemia

Phase 1b Clinical Trial, heart-1, Now Underway and Enrolling Patients with Heterozygous Familial Hypercholesterolemia in New Zealand Company Executing VERVE-101 Global Regulatory Strategy with Potential Clearances for a UK Clinical Trial Application and US Investigational New Drug Application in

RHEA-AI

neutral

06/13/22 6:30 AM

Nasdaq : VERV

management

Verve Therapeutics Appoints Experienced Biotechnology Executive, Alexander G. "Bo" Cumbo, to its Board of Directors

Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Alexander G. "Bo" Cumbo, chief executive officer and president of

RHEA-AI

very positive

VERV Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.vervetx.com
Security nameVerve Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees63

About Verve Therapeutics Inc

Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.